Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements (2026 and earlier)

Company Profile

Business Address 15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments417,267401,837381,143407,916291,375316,952
Cash and cash equivalent183,640112,72496,648175,78794,818176,210
Short-term investments233,627289,113284,495232,129196,557140,742
Restricted cash and investments 560     
Receivables87,10974,33660,24064,15348,05930,304
Inventory, net of allowances, customer advances and progress billings4,3723,8363,8732,7052,6202,846
Inventory4,3723,8363,8732,7052,6202,846
Prepaid expense13,47321,69529,1735,99914,6507,015
Other undisclosed current assets 1   1 
Total current assets:522,782501,704474,429480,773356,705357,117
Noncurrent Assets
Inventory, Noncurrent2,5322,5322,5322,5322,5332,533
Operating lease, right-of-use asset10,08010,2332293935521,802
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization11,6655,7463,1822,7872,3142,393
Long-term investments and receivables3,8703,0003,0003,0003,0003,000
Long-term investments3,8703,0003,0003,0003,0003,000
Intangible asset, including goodwill, after accumulated amortization7,3667,6067,8468,0868,3268,567
Intangible asset, excluding goodwill, after accumulated amortization7,3667,6067,8468,0868,3268,567
Restricted cash and investments2,0022,5632,5632,5632,562 
Other noncurrent assets1,8611,1771,213616999888
Total noncurrent assets:39,37632,85720,56519,97720,28619,183
TOTAL ASSETS:562,158534,561494,994500,750376,991376,300
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities104,416110,53984,80482,00876,68460,838
Accounts payable16,38740,64228,07528,38327,73926,815
Accrued liabilities88,02969,89756,72953,62548,94534,023
Other liabilities22,179     
Other undisclosed current liabilities9,1006,5115,4494,3003,9285,030
Total current liabilities:135,695117,05090,25386,30880,61265,868
Noncurrent Liabilities
Long-term debt and lease obligation72,43872,28172,12971,98471,84571,708
Long-term debt, excluding current maturities72,43872,28172,12971,98471,84571,708
Liabilities, other than long-term debt10,59910,148   1,240
Other liabilities10,59910,148   1,240
Total noncurrent liabilities:83,03782,42972,12971,98471,84572,948
Total liabilities:218,732199,479162,382158,292152,457138,816
Equity
Equity, attributable to parent343,426335,082332,612342,458224,534237,484
Common stock666666
Additional paid in capital769,667753,042738,237727,697584,559574,229
Accumulated other comprehensive income (loss)3812893985179346
Accumulated deficit(426,628)(418,255)(405,670)(385,330)(360,210)(337,097)
Total equity:343,426335,082332,612342,458224,534237,484
TOTAL LIABILITIES AND EQUITY:562,158534,561494,994500,750376,991376,300

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues151,668118,697102,66078,33566,40848,118
Cost of revenue(10,686)(8,109)(6,037)(4,971)(4,686)(3,142)
Cost of product and service sold      
Gross profit:140,982110,58896,62373,36461,72244,976
Operating expenses(148,958)(125,117)(118,807)(99,644)